DIAN-TU solanezumab arm (dominantly inherited AD prevention) terminated for futility 2020; soluble-Aβ-targeting MAb framework not viable in preclinical AD even in fully penetrant genetic risk.

Evidence span

DIAN-TU solanezumab arm (dominantly inherited AD prevention) terminated for futility 2020; soluble-Aβ-targeting MAb framework not viable in preclinical AD even in fully penetrant genetic risk.

Method & conditions

Evidence type

observational

Method

manual state transition

Species

Homo sapiens

Conditions

DIAN-TU-001 solanezumab arm (NCT01760005), dominantly inherited AD, halted Feb 2020.

Replicated

not yet

Confidence basis

operator-supplied frontier prior; review required